StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Tuesday morning. The brokerage issued a sell rating on the stock.

VNRX has been the subject of several other reports. Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. D. Boral Capital reissued a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a research note on Thursday, February 6th.

VolitionRx Trading Up 5.1 %

Shares of VolitionRx stock opened at $0.61 on Tuesday. The stock has a 50-day moving average price of $0.61 and a 200 day moving average price of $0.65. The company has a market cap of $56.60 million, a P/E ratio of -1.70 and a beta of 1.09. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.10.

Insider Transactions at VolitionRx

In other news, CEO Cameron John Reynolds purchased 139,811 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was bought at an average cost of $0.57 per share, with a total value of $79,692.27. Following the purchase, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Guy Archibald Innes acquired 174,764 shares of the stock in a transaction dated Monday, December 9th. The shares were bought at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the acquisition, the director now owns 617,085 shares in the company, valued at $351,738.45. The trade was a 39.51 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 358,266 shares of company stock valued at $204,212 in the last three months. Corporate insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after acquiring an additional 95,900 shares during the last quarter. Millennium Management LLC acquired a new position in shares of VolitionRx during the 4th quarter valued at about $36,000. Northern Trust Corp increased its holdings in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares during the last quarter. Lagoda Investment Management L.P. increased its holdings in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares during the last quarter. Finally, Two Sigma Securities LLC acquired a new position in shares of VolitionRx during the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.